Page 2 - Eli Mintz News Today

Compugen (NASDAQ:CGEN – Get Rating) and Graphite Bio (NASDAQ:GRPH – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations. Profitability This table compares Compugen and Graphite Bio’s net margins, […]

Compugen Ltd. (NASDAQ:CGEN – Get Rating) has received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average […]

Eagle Rock Investment Company LLC raised its holdings in shares of Compugen Ltd. (NASDAQ:CGEN – Get Rating) by 100.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 70,000 shares of the biotechnology company’s stock after purchasing an additional 35,000 […]

Compugen Ltd. (NASDAQ:CGEN – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for shares of Compugen in a research note issued to investors on Monday, February 27th. Jefferies Financial Group analyst C. Howerton expects that the biotechnology company will earn ($0.14) per share for […]

Analysts expect Compugen Ltd. (NASDAQ:CGEN – Get Rating) to announce earnings per share (EPS) of ($0.13) for the current quarter, Zacks reports. Zero analysts have issued estimates for Compugen’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.11). Compugen reported earnings of ($0.12) per share during […]

Compugen Ltd. (NASDAQ:CGEN – Get Rating) – Equities research analysts at Oppenheimer issued their FY2026 earnings per share estimates for Compugen in a report released on Friday, February 25th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($0.65) per share for the year. Oppenheimer has a “Outperform” rating and a […]

Compugen (NASDAQ:CGEN – Get Rating) had its target price decreased by Oppenheimer from $17.00 to $14.00 in a research note published on Friday, Analyst Price Targets reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock. Oppenheimer also issued estimates for Compugen’s FY2026 earnings at ($0.65) EPS. A number of other brokerages have […]